SOURCE: Faruqi & Faruqi LLP

March 29, 2014 10:15 ET

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in CytRx Corporation to Contact the Firm

NEW YORK, NY--(Marketwired - Mar 29, 2014) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in CytRx Corporation ("CytRx" or the "Company") (NASDAQ: CYTR) of the May 13, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against CytRx and the Company's CEO.

A complaint has been filed on behalf of all persons who purchased CytRx securities between November 20, 2013 and March 13, 2014, inclusive (the "Class Period") in the Central District of California.

The complaint alleges that the Company and its executives violated federal securities laws with respect to its disclosures concerning its business, operations, and prospects.

Specifically, the action alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) CytRx had hired a promoter for the purpose of increasing its share price; and (ii) the promoter did not properly disclose its paid marketing relationship in connection with the posting of misleading articles on behalf of CytRx.

On March 13, 2014, an article published on www.seekingalpha.com alleging that the Company's promoter utilized multiple aliases on third party websites, occasionally posing as hedge fund managers touting the stock.

Following this news, the Company's stock declined $0.61 per share, or over 12%, to close at $4.17 per share on March 13, 2014.

Request more information now by clicking here: www.faruqilaw.com/CYTR. There is no cost or obligation to you.

Take Action

If you invested in CytRx stock or options between November 20, 2013 and March 13, 2014 and would like to discuss your legal rights, visit www.faruqilaw.com/CYTR. You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding CytRx's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients. To keep track of the latest securities litigation news, follow us on Twitter at www.twitter.com/MergerActivity or on Facebook at www.facebook.com/FaruqiLaw.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

Contact Information

  • FARUQI & FARUQI, LLP
    369 Lexington Avenue, 10th Floor
    New York, NY 10017
    Attn: Richard Gonnello, Esq.
    Email Contact
    Francis McConville, Esq.
    Email Contact
    Telephone: (877) 247-4292 or (212) 983-9330